X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Healthy Interactions and Merck announce launch of digital health platform designed to enhance patient engagement in diabetes management

Content Team by Content Team
17th August 2018
in Press Statements

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Healthy Interactions, a global leader in health education, in collaboration with Merck , known as MSD outside the United States and Canada, announced the launch of map4health™ – a digital platform and mobile application in the U.S. that was designed to help facilitate and enhance communications between diabetes patients and educators.
This technology was developed as an extension of the Journey for Control collaboration between Healthy Interactions and Merck, and will make its debut today at the 2018 American Association of Diabetes Educators (AADE) Annual Conference in Baltimore.

Map4health is designed as a platform to help improve the quality of diabetes patient support in between in-person coaching sessions by enabling patients to connect with educators through text and video-chat, as well as providing weekly digital activities to sustain patient engagement. Patients may choose to securely log health information that their educators are able to review and respond to within the platform.

“Healthy Interactions has collaborated with Merck for over 10 years on Journey for Control to encourage patients living with diabetes to become more engaged stewards of their health,” said Paul Lasiuk, co-founder and chief executive officer, Healthy Interactions. “Today, we are proud to introduce map4health, and believe this tool will further enhance the positive impact that diabetes educators are making in the lives of their patients.”

In 2007, Healthy Interactions and Merck, also in collaboration with the American Diabetes Association (ADA), launched Journey for Control – a patient-centric education initiative targeting diabetes educators and utilizing the U.S. Diabetes Conversation Map® – to collaborate on developing tools focused on lifestyle and behavioral change to help healthcare providers improve diabetes management for people living with the disease.

“The American Diabetes Association supports technology-based methods, along with individual and group settings, for the delivery of effective diabetes self-management education and support,” according to Matt Petersen, vice president at the American Diabetes Association. “The ADA has been extremely satisfied with the ability to connect providers and patients that has been enabled through our collaboration with Healthy Interactions and Merck.”

“We are thrilled our work with Healthy Interactions will provide diabetes patients and educators a digital platform for dialogue and personalized self-management tools,” added Lisa French, associate vice president, strategy and commercial model innovation, Merck. For more information on map4health, please visit www.map4health.com.

About the Healthy Interactions and Merck Collaboration
The collaboration between Healthy Interactions and Merck began in 2007 to address unmet educational needs in diabetes management.

Map4health, launched in 2018, is an evolution of the companies’ 11-year collaboration aimed to better equip health educators to deliver improved patient support and education for patients living with diabetes. The digital tool is designed to foster communications to help patients meet their healthcare goals. The map4health platform is owned and developed by Healthy Interactions in collaboration with Merck and can be integrated into existing diabetes self-management education and support (DSMES) programs, such as Journey for Control.

About Healthy Interactions, Inc.
A global leader in health education, Healthy Interactions, Inc. is devoted to driving Personal Health Engagement—our term for helping individuals commit to healthier actions. We create powerful educational approaches that inspire valuable insights and change personal health behaviors. We build partnerships with leading medical and disease associations, not-for-profit organizations, corporations, and healthcare professionals. Our approaches enable millions of people to take control of their health and live their best lives. Our digital tools empower health care consumers to move toward their goals by providing information, tracking, and ongoing interactions with peers and health educators. The result is that patients become more active partners in their health, which improves the outcomes of their diseases. We partner with health systems and clinics across the U.S. and with pharmaceutical companies that sponsor our programs around the world.

About Merck
For more than a century, Merck, a leading global bio-pharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com

Previous Post

Eisai And Merck announce FDA approval of LENVIMA capsules for first-line treatment of Unresectable Hepatocellular Carcinoma

Next Post

U.S. FDA approves opdivo as the first new medication in nearly 20 years for certain patients with previously treated small cell lung cancer

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Next Post

U.S. FDA approves opdivo as the first new medication in nearly 20 years for certain patients with previously treated small cell lung cancer

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In